OrphoMed Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 11

Employees
  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $5.5M

  • Investors
  • 5

OrphoMed General Information

Description

Developer of dimer therapeutics platform designed to treat Irritable Bowel Syndrome with Diarrhea, Opioid Bowel Dysfunction, and pain. The company's platform focuses on developing therapies for irritable bowel syndrome with diarrhea, acute and chronic pain, and cystic fibrosis, enabling patients to get the first-line treatment for gastrointestinal disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
  • 50 Francisco Street
  • Suite 245
  • San Francisco, CA 94133
  • United States
+1 (415) 000-0000

OrphoMed Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OrphoMed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 28-Apr-2021 $5.5M 000.00 0000 Completed Clinical Trials - Phase 2
2. Debt - PPP 30-Apr-2020 0000 Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 24-May-2017 $39M $39M 000.00 Completed Clinical Trials - Phase 2
To view OrphoMed’s complete valuation and funding history, request access »

OrphoMed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view OrphoMed’s complete cap table history, request access »

OrphoMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of dimer therapeutics platform designed to treat Irritable Bowel Syndrome with Diarrhea, Opioid Bowel Dysfunct
Biotechnology
San Francisco, CA
11 As of 2021
000.00
000 0000-00-00
00000000000 000.00

000000

agna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex e
0000 000000000
Tel Aviv, Israel
000 As of 0000
00000
000000000 00000

000000

ommodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fu
0000000000000
South San Francisco, CA
00000 As of 0000
000.00
0000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OrphoMed Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
RedHill Biopharma Formerly VC-backed Tel Aviv, Israel 000 00000 000000000 00000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 0000000000
00000000 000000000 Formerly VC-backed Boston, MA 000 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
You’re viewing 5 of 26 competitors. Get the full list »

OrphoMed Patents

OrphoMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11236067-B2 Compound for treating cystic fibrosis Active 12-Jul-2019 0000000000 00
US-20210009556-A1 Compound for treating cystic fibrosis Active 12-Jul-2019 0000000000
AU-2016344308-A1 Methods of treating pain or fever using pharmaceutically active acetaminophen dimers linked through phenolic hydroxyl groups Inactive 26-Oct-2015 0000000000
CA-3001851-A1 Methods of treating pain using pharmaceutically active acetaminophen dimers linked through phenolic hydroxyl groups Inactive 26-Oct-2015 0000000000
EP-3368027-A4 Methods of treating pain or fever using pharmaceutically active acetaminophen dimers linked through phenolic hydroxyl groups Active 26-Oct-2015 A61K31/167
To view OrphoMed’s complete patent history, request access »

OrphoMed Executive Team (12)

Name Title Board Seat Contact Info
Gregory Beyer Chief Financial Officer
Nikhilesh Singh Ph.D Co-Founder, Chief Scientific Officer & Board Member
Frank Steinberg Co-Founder & Head of Medical Oversight
Lisa Turner Vice President, Clinical Operations
Virginia Sanders Ph.D Vice President of Preclinical Development & Program Management
You’re viewing 5 of 12 executive team members. Get the full list »

OrphoMed Board Members (11)

Name Representing Role Since
Arthur Pappas Pappas Capital Board Member 000 0000
Blake Wu Self Board Member 000 0000
Gary Phillips MD Self Chief Executive Officer, President & Board Member 000 0000
Kenneth Widder MD Self Executive Chairman 000 0000
Michael Chao MD Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

OrphoMed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OrphoMed Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Mario Family Fund Other Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Pappas Capital Venture Capital Minority 000 0000 000000 0
Relativity Healthcare Partners Venture Capital Minority 000 0000 000000 0
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
To view OrphoMed’s complete investors history, request access »